Dyne Therapeutics, Inc. (NASDAQ:DYN) Shares Acquired by Northern Trust Corp

Northern Trust Corp increased its position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) by 7.7% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 777,013 shares of the company’s stock after buying an additional 55,511 shares during the period. Northern Trust Corp’s holdings in Dyne Therapeutics were worth $18,306,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. KBC Group NV grew its stake in shares of Dyne Therapeutics by 45.3% during the fourth quarter. KBC Group NV now owns 3,135 shares of the company’s stock valued at $74,000 after acquiring an additional 978 shares in the last quarter. Summit Investment Advisors Inc. grew its stake in Dyne Therapeutics by 9.1% during the 4th quarter. Summit Investment Advisors Inc. now owns 8,627 shares of the company’s stock valued at $203,000 after purchasing an additional 721 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new stake in Dyne Therapeutics during the 4th quarter worth approximately $257,000. Magnetar Financial LLC purchased a new stake in Dyne Therapeutics during the 4th quarter worth approximately $263,000. Finally, E Fund Management Co. Ltd. grew its position in shares of Dyne Therapeutics by 11.8% during the fourth quarter. E Fund Management Co. Ltd. now owns 11,848 shares of the company’s stock worth $279,000 after buying an additional 1,249 shares in the last quarter. Institutional investors and hedge funds own 96.68% of the company’s stock.

Insider Buying and Selling at Dyne Therapeutics

In other news, insider Oxana Beskrovnaya sold 2,598 shares of Dyne Therapeutics stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total transaction of $36,242.10. Following the transaction, the insider now directly owns 199,087 shares in the company, valued at approximately $2,777,263.65. This trade represents a 1.29% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In the last 90 days, insiders have sold 6,237 shares of company stock valued at $77,760. Company insiders own 14.14% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on DYN shares. Scotiabank began coverage on shares of Dyne Therapeutics in a research note on Friday, March 7th. They set a “sector outperform” rating and a $50.00 price objective on the stock. Chardan Capital reaffirmed a “buy” rating and set a $50.00 price target on shares of Dyne Therapeutics in a research report on Friday, May 9th. BMO Capital Markets started coverage on Dyne Therapeutics in a report on Wednesday, March 12th. They issued an “outperform” rating and a $50.00 price objective for the company. Piper Sandler reduced their target price on Dyne Therapeutics from $53.00 to $48.00 and set an “overweight” rating on the stock in a report on Friday, February 28th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $45.00 target price on shares of Dyne Therapeutics in a research report on Tuesday, January 14th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, twelve have given a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $46.85.

Dyne Therapeutics Stock Performance

DYN stock opened at $12.10 on Wednesday. Dyne Therapeutics, Inc. has a 1 year low of $6.36 and a 1 year high of $47.45. The stock has a market capitalization of $1.37 billion, a price-to-earnings ratio of -3.40 and a beta of 1.19. The stock’s fifty day moving average is $10.37 and its two-hundred day moving average is $17.81.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.17). As a group, analysts predict that Dyne Therapeutics, Inc. will post -3.44 EPS for the current fiscal year.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.